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In this review, we consider the ways in which vasopressin and oxytocin have been measured since
their first discovery. Two different ways of measuring oxytocin in widespread use currently give
values in human plasma that differ by two orders of magnitude, and the values measured by these
two methods in the same samples show no correlation. The notion that we should accept this
seems absurd. Either one (or both) methods is not measuring oxytocin, or, by ‘oxytocin’, the scien-
tists that use these different methods mean something very different. If these communities are to
talk to each other, it is important to validate one method and invalidate the other, or else to estab-
lish exactly what each community understands by ‘oxytocin’. A similar issue concerns vasopressin:
again, different ways of measuring vasopressin give values in human plasma that differ by two
orders of magnitude, and it appears that the same explanation for discrepant oxytocin measure-
ments applies to discrepant vasopressin measurements. The first assays for oxytocin and vaso-
pressin measured biological activity directly. When immunoassays were introduced, they
encountered problems: high molecular weight factors in raw plasma interfered with the binding of
antibodies to the hormones, leading to high and erroneous readings. When these interfering fac-
tors were removed by extraction of plasma samples, immunoassays gave measurements consistent
with bioassays, with measures of turnover and with the sensitivity of target tissues to exogenous
hormone. However, many recent papers use an enzyme-linked immunoassay to measure plasma
levels without extracting the samples. Like the first radioimmunassays of unextracted plasma, this
generates impossibly high and wholly erroneous measurements.
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Introduction
Vasopressin and oxytocin are released into the circulation from the
axon terminals of magnocellular hypothalamic neurones that project
to the posterior pituitary. They are also released within the brain
from the dendrites of these neurones, in a manner regulated semi-
independently of axonal release. In addition, diverse populations of
functionally separate neurones release oxytocin and vasopressin
within the brain to regulate diverse physiological processes and
behaviours (1). The involvement of these peptides in social beha-
viour has led some to measure them in plasma, with the assump-
tion that these might be indicative of their activity in the brain. The
sense behind this has been questioned (2). Furthermore, more than
100 papers have recently been published using assays that have
been claimed to measure oxytocin and vasopressin in human
plasma simply and reliably (for example 3–6), but which report
levels massively inconsistent with previous assays. Here, we seek to
describe and explain these inconsistencies.
A brief history
In 1906, as an aside in a study of the actions of ergot, Dale (7)
reported that extracts of the posterior pituitary gland could stimu-
late uterine contractions. In 1909, Bell (8) conducted the first clini-
cal trial of this extract, reporting that it powerfully contracted the
uterus of women in labour. The extract swiftly entered use in
obstetric practice and, in 1913, the Professor of Obstetrics and
Gynecology at the University of Toronto declared that ‘it has been
employed in practically every obstetrical clinic throughout this con-
tinent and in Britain and Europe’ (9).
In 1925, a Committee of the League of Nations adopted the
United States Pharmacopeia Standard Reference Powder as an
international standard (10). This was made from the whole posterior
lobes of cattle: the glands were collected immediately after death
and ground in acetone to remove water and fat, with 0.5 mg of
powder declared equivalent to one International Unit (IU). These
extracts were standardised for their oxytocic activity by a bioassay
(on guinea pig uterus), although it was clear that they contained at
least two active principles: one with both a pressor activity and
antidiuretic activity, and one with oxytocic activity (11). In 1928,
Kamm (12) separated and concentrated the two principles, and
named them ‘vasopressin’ and ‘oxytocin’.
In the 1950s, the amino acid sequences and structures of oxy-
tocin and vasopressin were elucidated, followed shortly by their
synthesis. However, the units by which they were measured
remained tied to biological activity. In 1955, the Third International
Standard was established by an international collaboration: samples
of posterior pituitary extract were sent to 19 laboratories in 10
countries, where 185 assays were carried out to define its oxytocic,
vasopressor and antidiuretic potency (13). The standard was
adjusted to have the same biological activity as previous standards,
and its activity was compared with that of pure synthesised pep-
tide. The current (4th) International Standard for Oxytocin assigns
1 mg of oxytocin a potency of 600 IU (14), and the International
Standard for Vasopressin assigns 1 mg of vasopressin a potency of
410 IU (15), and these are the values used for conversions in the
present review.
By the end of the 1950s, it was accepted that oxytocin and
vasopressin were synthesised in hypothalamic neurones, packaged
into vesicles in the cell body and transported down the axons for
storage in the axon terminals in the pituitary (16). The vesicles cer-
tainly contained much more than the hormones: Gainer et al.
(17,18) identified two putative precursor proteins in the hypothala-
mus, and showed that they were packaged into the neurosecretory
vesicles where they were processed to produce the peptides and
their associated neurophysins. The structures of the precursors were
determined (19), and neurophysins, now established to be elements
of the precursors, were thus revealed to be stored and secreted
with their associated peptides in equimolar amounts.
Morris (20) then sought to establish exactly how much hormone
is present in each vesicle. By counting vesicles in ultrathin sections
of the pituitary under the electron microscope, he estimated that
the rat posterior pituitary contains 1.44 9 1010 vesicles and, from
the pituitary content of oxytocin and vasopressin measured by
bioassays, he deduced that each vesicle contains approximately
84 000 hormone molecules. This calculation assumed that all of the
hormone content was contained in the vesicles and so, with Jean
Nordmann, he set about checking this. They prepared fractions of
posterior pituitary in which the number of vesicles could be esti-
mated, by adding latex particles of similar size, pelleting the mix-
ture, and measuring the ratio of latex particles to vesicles (21).
They measured hormone content by both radioimmunoassays and
bioassays, and neurophysin content by radioimmunoassay, and con-
cluded that vesicles from both oxen and rats contained approxi-
mately 85 000 molecules of hormone and neurophysin. The close
agreement with the estimate derived by morphometry of the whole
gland confirmed that all hormone was contained within the
vesicles. The estimated number of molecules in each vesicle was
close to the theoretical maximum in the space available, and so
could not be a significant underestimate.
Oxytocin and vasopressin act at four receptors: the oxytocin
receptor (22); the V2 receptor, which accounts for the antidiuretic
actions of vasopressin (23,24); the V1b receptor (25), which
accounts for vasopressin effects on adrenocorticotrophin release;
and the V1a receptor, which accounts for the pressor activity of
vasopressin (26). These receptors bind their preferred ligands with
nanomolar affinity, although each hormone can act at receptors for
the other if present at a 100-fold excess. Receptor affinity is impor-
tant for comparing the potency of different peptides at a given tar-
get, although it is a poor guide to the concentrations needed to
elicit biological activity. The effective concentration in any tissue
depends less on the receptor affinity than on the receptor density.
In the periphery, V2 receptors are at highest density in the kidney,
and oxytocin receptors are at highest density in the uterus and
mammary gland.
Bioassays of vasopressin
Initially, the main ways of quantifying oxytocin and vasopressin
were by bioassays. The ‘pressor’ bioassay measured the blood pres-
sure response to i.v. injection of extracts in rats (27). Specificity
was a problem because other factors present in samples might also
raise blood pressure. Accordingly, in the protocol of Dekanski (27),
rats were injected with an a-adrenergic antagonist to abolish the
pressor responses to adrenaline and noradrenaline, which were the
major confounding factors.
Bioassays for antidiuretic activity measured the degree to which
injections of extract concentrated the urine of a water-loaded rat
(28), and these had fewer problems with specificity than pressor
assays. By the late 1950s, antidiuretic assays could measure vaso-
pressin at doses as low as 4 lU (10 pg) (29), a sensitivity achieved
by injecting rats with alcohol to suppress endogenous vasopressin
secretion and by maintaining a constant water load to stabilise the
preparation for repeated measurements. These assays were still not
sufficiently sensitive to measure in plasma until Heller and Stulc
(30) introduced another refinement; using rats with exteriorised uri-
nary bladders, they could detect concentrations above 0.65 lU/ml,
and they estimated that vasopressin circulated in normally hydrated
men at approximately 1.7 lU/ml (4 pg/ml).
Using a modified version of this assay, Czaczkes et al. (31) took
blood samples from men and assayed them without extraction or
concentration. Vasopressin was undetectable (< 0.25 lU/ml) in
samples taken 1–2 h after an oral water load, but, during 24 h of
dehydration, concentrations rose to approximately 18 lU/ml
(44 pg/ml), whereas urine osmolarity increased from approximately
70 mOsm/l to more than 1000 mOsm/l. The range agreed with that
reported by Heller and Stulc (30), and also with that reported by
Yoshida et al. (32) who found 1.9 lU/ml (4.6 pg/ml) in extracted
samples from normally hydrated subjects, rising to 6.5 lU/ml
(16 pg/ml) after modest dehydration.
The antidiuretic bioassay was capable of high sensitivity and pre-
cision, and it yielded some remarkable insights. For example, Segar
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and Moore (33) found that vasopressin concentrations in man
depend on both position and on ambient temperature. In 79 control
subjects who were sitting comfortably, the mean plasma concentra-
tion was 1.65 lU/ml (4 pg/ml) compared to 0.4 lU/ml (1 pg/ml)
when lying down and 3.1 lU/ml (8 pg/ml) when standing. The
responses to posture reflect the sensitivity of vasopressin secretion
in man to central hypovolaemia, and were later confirmed
by radioimmunoassay (34–36). After 2 h of exposure to 50 °C,
levels in control subjects rose to 5.2 lU/ml (13 pg/ml), falling
again within 15 min at 26 °C. The sensitivity to temperature was
also later confirmed by a radioimmunoassay (37) and, in 2008, it
was reported that vasopressin neurones are intrinsically ther-
mosensitive through membrane channels expressed from the trpv1
gene (38).
From such studies came the agreement that the normal plasma
concentration of vasopressin in man is below 2 lU/ml (5 pg/ml)
(39), with this increasing several fold after 24 h of dehydration.
These conclusions were also consistent with studies of antidiuretic
responses to exogenous vasopressin: Theobald (40) first showed
that injection of 5–10 mU (12–24 ng) vasopressin produced near-
maximal antidiuresis in man (see also 41–43), and studies using i.v.
infusions of vasopressin in water-loaded subjects indicated that the
kidney responds to changes in the rate of vasopressin secretion of
< 1 pg/min/kg, and also that the rate required to produce isosmo-
lar urine during overhydration is approximately 3 pg/min/kg (44–
46). A similar sensitivity to low levels of vasopressin was found in
dogs (47,48).
Bioactivity of oxytocin
Antidiuretic assays benefitted from the extreme sensitivity of the
urine concentrating mechanisms of the kidney, but practical bioas-
says for oxytocin were less sensitive. The uterus is most sensitive to
oxytocin in late pregnancy (22) but, at this stage, the uterus con-
tracts spontaneously, complicating the measurement of samples.
Bioassays using the nonpregnant rat uterus (49) and mammary
gland bioassays (42) could generally detect only concentrations
above 25 lU/ml (42 pg/ml). The most sensitive bioassays used
mouse mammary strips and could detect 4 lU/ml (7 pg/ml) in
0.5 ml of sample (50), although even this was still not sufficiently
sensitive to measure levels in raw plasma.
The first estimates of the circulating concentration of oxytocin
in man came not from any direct bioassay but were a combina-
tion of deduction and experiment (40,51). Theobald (51), who had
shown that very low doses of vasopressin evoked antidiuresis in
man, speculated that similarly low doses of oxytocin would induce
labour, and he showed that drips delivering 1–5 mU/min (2–8 ng/
min) were indeed effective. He concluded that the physiological
concentration of oxytocin which initiates labour ‘could not be
more and might well be less’ than that achieved by this rate
of delivery. Saameli (52) drew similar conclusions: he calculated
that the half-life of oxytocin in pregnant women was approxi-
mately 3–4 min, and also that uterine contractions were initiated
by infusions that raised plasma concentrations by 3 lU/ml
(5 pg/ml).
Although oxytocin infusions advance labour, and although there
is a modest increase in plasma oxytocin concentrations before
delivery in most animal studies, many have doubted whether there
is any increase in oxytocin secretion before delivery in women
(42,53–55). They have proposed that it is not an increase in oxy-
tocin secretion, but the increase in sensitivity of the uterus to oxy-
tocin that initiates labour in women (56). Nevertheless, augmenting
oxytocin concentrations with infusions can advance delivery in all
mammals studied. Most protocols for inducing labour in women
start by infusing oxytocin at 1–2 mU/min (1.7–3.3 ng/min), rising
to 20–30 mU/min for at most 5 h, with a maximum total dose of
5 IU (8 lg). Higher doses than these are not more effective (57),
and some have suggested that even these rates are higher than
necessary. Dawood (58) advised that infusions should not exceed
2–8 mU/min and reported that oxytocin given as pulses, beginning
with 1 mU/min every 8 min and doubling the pulse dose every
24 min, was as efficient as continuous infusion. Oxytocin is given
at much higher doses to prevent post-partum haemorrhage (59),
but this action appears to be mediated not by oxytocin receptors
but by V1a receptors on the uterine artery (60).
Theobald (51) also studied the effect of suckling during the first
10 days of the puerperium; uterine contractions began within
3 min of the onset of suckling, and this effect was matched by a
single i.v. injection of 10 mU (17 ng) oxytocin. Other studies
recorded intramammary pressure in women in the week after deliv-
ery, and noted that i.v. injections of just 0.1–2 mU (0.2–3 ng)
caused sharp increases in intramammary pressure (61), and when a
baby suckled at the uncannulated breast, sharp rises in intramam-
mary pressure were seen in the cannulated gland, similar to those
evoked by i.v. injection of approximately 5 mU of oxytocin (62,63).
The human myopithelium proved to be more sensitive to oxytocin
than in any other species studied previously. Measurements by
radioimmunoassay reported that, during suckling in women, inter-
mittent pulses were observed with a mean amplitude of just
approximately 9 pg/ml from a basal level of approximately 2 pg/ml,
as expected for bolus release of approximately 17 ng (64).
In lactating rats, suckling results in intermittent activation of
oxytocin neurones: every 5–10 min, they discharge a burst of
approximately 150 action potentials over 2–3 s. Each burst is fol-
lowed by an increase in intramammary pressure that can be mim-
icked by i.v. injection of approximately 0.5 mU (0.8 ng) of oxytocin
(16,65). In anaesthetised rats, similar increases in intramammary
pressure can be produced by electrically stimulating the pituitary
stalk for 4 s at 50 Hz to evoke a burst-like train of action poten-
tials (65). Similar stimulation of the isolated posterior pituitary
gland in vitro evokes secretion into the bathing medium, which can
be measured by radioimmunoassay without problems of sample
matrix interference because the assay standard curve is generated
in the same medium. Stimulation at 50 Hz releases approximately
7 pg of oxytocin per stimulus pulse (66), which is close to the
release estimated from the intramammary pressure response to a
similar electrical stimulation in vivo.
The plasma volume of a rat is approximately 4 ml/100 g (67),
and so a burst that releases 0.5 mU (0.8 ng) oxytocin should raise
circulating concentrations in a 300 g rat by approximately 70 pg/ml.
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Higuchi et al. (68) developed a radioimmunoassay that allowed oxy-
tocin to be measured in unextracted rat plasma, and took samples
at the time of suckling-induced milk let-down, as recognised by
stretching movements of the suckling pups. Plasma concentrations
rose from 16.5 pg/ml to approximately 65 pg/ml, and declined with
a half-life of approximately 1.5 min. Because the behavioural
response is apparent only with a delay after milk let-down, these
samples may have missed the full peak of plasma oxytocin,
although the agreement is still close.
In pigs (body weight 150–200 kg), suckling evokes increases in
intramammary pressure equivalent to those induced by i.v. injection
of 50 mU (83 ng) of oxytocin (69). For a plasma volume of 5 l,
these would raise plasma concentrations by approximately 17 pg/
ml, which is close to the peak concentration (approximately 18 pg/
ml) measured by radioimmunoassay during suckling-induced milk
ejection. Larger animals show even higher sensitivity to oxytocin; in
horses (body weight 543 kg), with injections of just 5–10 mU
mimic the suckling-induced increase in intramammary pressure
(70).
Across mammalian species, blood volume is linearly proportional
to body mass, although the mass of the pituitary is proportional
only to the log of body mass (71). Consistent with this, the human
posterior pituitary contains approximately 21 lg of oxytocin (72–
74), whereas that of the rat contains 0.5–1 lg. Given a 400-fold
difference in plasma volume but only a 40-fold difference in pitu-
itary oxytocin content, it is likely that the higher sensitivity of the
mammary gland and uterus in humans parallels the lower amounts
of oxytocin available for secretion from the pituitary.
Immunoassays
By the end of the 20th century, bioassays were still ‘of critical
importance’ in the discovery of novel antagonists and antagonists
of vasopressin and oxytocin because biological activity cannot be
inferred from structure alone (75). However, bioassays were time
consuming and expensive in their use of animals, and they had
been extensively replaced by immunoassays that could assay many
samples quickly. In 1973, Chard (76) noted that best immunoassays
for vasopressin were no more sensitive than the best bioassays; the
same is still true today for most radioimmunoassays and most
enzyme-linked immunoassays (ELISAs). However, bioassays are less
specific because of the cross-reactivity of vasopressin and oxytocin
with their respective receptors (76).
Radioimmunoassays and competitive ELISAs both depend on the
reaction between the hormone in a sample and a fixed amount of
antibody added to it: some of the hormone will bind to the anti-
body, whjereas some remains ‘free’, in a reaction governed by the
law of mass action. When a fixed amount of radiolabelled or
enzyme-conjugated hormone is added, it competes for binding to
the antibody with the hormone already present, and so less labelled
hormone will bind when more unlabelled hormone is present. In
radioimmunoassays, the bound fraction is then precipitated, usually
with a second antibody that recognises the original antibody. The
amount of label in the pellet is measured, and the values are com-
pared with a standard curve generated from known concentrations
of unlabelled hormone in assay buffer (processed in the same way
as the samples). This is a hyperbolic curve, which, after allowing for
nonspecific binding, can be reduced by a logit-log transformation
to a straight line (77). In ELISAs, the bound fraction is retained in
the assay plate, and the amount of bound label is measured by
optical density, giving a similar hyperbolic standard curve.
There were considerable difficulties in developing immunoassays
for vasopressin and oxytocin. Because these have a low molecular
weight, they are poor immunogens, making the preparation of
high-affinity antisera difficult, and circulating levels were clearly
very low. Thus, close attention was given to extraction and concen-
tration procedures (76). In 1970, Robertson et al. (78) described one
of the first radioimmunoassays to measure plasma vasopressin in
man. This assay was sensitive to 1 pg/ml (0.3 mU/ml) but, when
whole plasma was assayed, apparent concentrations were ‘several
hundredfold higher than anticipated, failed to fluctuate appropri-
ately in response to physiological manipulation or in disease states,
and were not reduced substantially by dialysis of the plasma under
conditions that completely removed vasopressin’.
Robertson et al. (78) set about understanding why these initial
radioimmunoassay measurements were erroneous. By filtering
plasma samples on G-25 Sephadex, they resolved three peaks of
‘immunoreactivity’, only the third and smallest of which was con-
sistent with true vasopressin, being recovered in the same location
as pure vasopressin (78). The first peak accounted for a 67% loss
of binding of antibody to vasopressin, and the second peak
accounted for a further 30% loss. Neither of these apparent ‘im-
munoreactivities’ were displaced by an excess of cold vasopressin,
indicating that they did not involve competitive binding of vaso-
pressin, but occlusion of antibody recognition of vasopressin. The
immunoreactivity in the third peak reproduced the expected rela-
tionship with plasma osmotic pressure in normal adults, the
expected high levels in nephrogenic diabetes insipidus (in which the
kidney is unresponsive to vasopressin, resulting in high plasma
osmolarity and elevated vasopressin secretion) and the expected
low levels in pituitary diabetes insipidus (in which vasopressin
secretion is deficient as a result of genetic mutation or to damage
to the hypothalamus or pituitary). After accounting for the plasma
matrix interference, Robertson et al. (78) calculated that normal
plasma concentrations of vasopressin in man were approximately
1 pg/ml, increasing to approximately 10 pg/ml with dehydration.
Problems with immunoassays
Problems can come from factors such as heparin or low pH or high
osmolality that interfere with the antigen–antibody reaction. High
salt concentrations have a nonlinear effect, and serial dilutions of
samples with a high salt content produce measurements that do
not parallel the standard curve. In some cases, an antibody might
recognise elements unrelated to the antigen against which it was
raised. Antibodies are sensitive to differences in amino acid
sequence, although they recognise the structure of a molecule, not
its amino acid sequence per se, and so unrelated molecules might
cross-react (76,79). However, it is unlikely that an antibody will
recognise a different ligand with higher affinity than it has for the
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ligand to which it was raised; it may recognise other ligands with
lower affinity, although this presents a major problem only if that
different ligand is present at higher concentrations.
For peptide assays, interference mainly comes from plasma pro-
teins that bind to the primary antibody, impairing its ability to bind
hormone, leading to an excess of free label that is erroneously
measured as a high concentration of hormone (78) (Fig. 1). Such
interference has also been recognised in immunoassays for chole-
cystokinin (80), parathyroid hormone (81), thyrotropic hormone
(82), glucagon (83), secretin (84,85), angiotensin (86), growth hor-
mone (87), vasoactive intestinal peptide (88), gonadotrophins (89)
and gonadotrophin-releasing hormone (90), all of which were
resolved by sample extraction. When describing their vasopressin
assay, Baylis and Heath (91) emphasised that ‘even small increases
in protein concentration lower binding and therefore careful control
of extract protein concentration is needed to avoid the misinterpre-
tation that a fall in binding is due to immunoreactive vasopressin’.
At that time, seven other vasopressin radioimmunoassays had been
described, using different antibodies and different extraction proce-
dures. All had reported plasma concentrations of 1–10 pg/ml, and
all showed that concentrations changed with physiological condi-
tions in the manner expected from bioassays.
Fyhrquist et al. (92) circumvented the problem of protein inter-
ference by using individual plasma blanks spiked with a known
amount of vasopressin to correct measured values. In unextracted
plasma from healthy subjects, they found a mean vasopressin con-
centration of 2 pg/ml in the supine position and 6.2 pg/ml in the
upright position, which is in agreement with the levels measured in
bioassays by Segar and Moore (33). Henneberry et al. (93) took a
different approach: they assayed unextracted samples using stan-
dard curves generated in charcoal-filtered plasma, and reported
basal levels of 1.8 pg/ml, rising to 6.3 pg/ml after a saline infusion
that raised plasma osmotic pressure from 280 to 293 mOsm/l.
Immunoassays for oxytocin
By the 1980s, many laboratories had generated radioimmunoassays
for oxytocin, using independently produced antibodies (58,72–
74,94–98)] and most, but not all (99,100), required extraction. With
few exceptions, assays in extracted plasma reported basal levels of
< 5 pg/ml in man: of 17 studies reviewed by Szeto et al. (101),
only two reported higher levels; the highest (71 pg/ml) were in
samples taken from the corpus cavernosum of the penis, a circum-
stance that might be expected to affect hormone secretion.
Antibodies do not recognise the whole molecule, and so an
immunoassay may overestimate hormone concentrations by mea-
suring fragments of no physiological significance (76). Generally,
antibodies are raised to the tail end of oxytocin, which confers its
biological activity. When oxytocin or vasopressin are secreted, the
entire contents of the vesicle are discharged, including elements of
incompletely processed precursor that may not be biologically
active. If an extended or truncated oxytocin molecule has full bio-
logical activity, then, to all intents and purposes, it is oxytocin, as
understood to be the active molecule secreted from the posterior
pituitary. Problems might arise less from assays recognising such
forms, than from failing to recognise them, leading to an underes-
timate of the levels of bioactive oxytocin. However, the major dis-
crepancies are that some immunoassays massively overestimate
oxytocin concentrations by comparison with bioassays.
Overestimation might arise if an antibody recognises a fragment
with higher affinity than the native peptide, although this is unli-
kely. Overestimation can also arise when enzymes are present that
degrade oxytocin. The plasma of late pregnant women contains
abundant oxytocinase, which inactivates oxytocin by splitting the
peptide linkage between the cysteine and tyrosine residues (102).
When oxytocin is incubated in this plasma, there is a rapid loss of
biological activity but, after 2 h, oxytocin ‘immunoreactivity’
exceeds bioactivity by three-fold. The obvious explanation is that
oxytocinase in the sample also degrades the labelled oxytocin. The
consequence will be that less label will bind to antibody, leading to
overestimation of the amount of oxytocin (76). Fortunately, enzy-
matic degradation of oxytocin is a problem only when measuring in
plasma from pregnant women (54), and extraction procedures can
remove such enzymes efficiently.
The relationship between plasma concentrations and rates
of production and secretion
How much hormone is present in plasma depends on the rate at
which it is secreted, the volume in which it is dispersed, and the
rate at which it is cleared. Hormone is secreted into the extracellu-
lar fluid of the pituitary gland; from there, it enters blood that
drains into the jugular vein and, unless it is bound to much larger
molecules in the plasma, it will pass relatively freely between the
plasma and the extravascular fluid. Thus, the ‘distribution volume’
will be between the total plasma volume and the total extracellular
fluid volume. The clearance can be measured by the decline of hor-
mone in blood samples taken after an i.v. injection or at the end of
a steady-state infusion, usually by a half-life approximation to an
exponential fit to the first, fast phase of disappearance. Other stud-
ies prefer to measure the metabolic clearance rate (MCR), by infus-
ing hormone at a fixed rate until plasma concentrations reach an
equilibrium. At equilibrium, the delivery of oxytocin must equal its
clearance, and the MCR is calculated from the delivery rate and the
measured concentration. The MCR is measured in units of l/min,
being the equivalent volume of fluid from which hormone is com-
pletely cleared every 1 min.
Clearance of vasopressin
In dogs, Lauson and Bacanegra (103) reported that the antidiuretic
activity of exogenous vasopressin disappeared with a half-life of
approximately 5.4 min. In experiments on the isolated, perifused
kidney, it was found that, when vasopressin was infused at 100–
120 ng/min, approximately 38% of it was cleared in each passage
through the kidney. More was lost from the blood than was found
in the urine, and Lauson and Bacanegra (103) concluded that, at
physiological levels (< 25 pg/ml), most of the vasopressin in the
plasma is bound to protein and is cleared by the tubular cells of
the kidney by enzymatic inactivation and secretion. At higher
© 2016 The Authors. Journal of Neuroendocrinology published by
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concentrations, more of the vasopressin is unbound, and some of
this is filtered at the glomerulus and excreted into urine.
In rats, Ginsburg and Heller (104) estimated that the initial half-
life of exogenously administered vasopressin was less than 1 min.
From experiments in acutely nephrectomised rats, and by ligating
arteries to reduce blood flow through the liver, it was concluded
that most of the vasopressin was cleared by the kidneys and liver.
In similar studies on rabbits, vasopressin was cleared with a
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Fig. 1. (A) Illustrates the principles underlying competitive immunoassays and the problem posed by plasma matrix interference. In an immunoassay, a sample
containing an unknown amount of hormone (in blue) is mixed with a known amount of labelled hormone (red) and introduced to a given amount of antibody
(orange). The labelled and unlabelled hormone compete for binding to the antibody: the more hormone in the sample, the less bound labelled hormone, which
is what is measured in an immunoassay. Unextracted plasma contains large molecules that can bind nonspecifically to antibodies (green), preventing them
from binding to antigen. Accordingly, less labelled hormone can bind to the antibody, and this is erroneously measured as an excess of hormone in the sam-
ple. When a ligand L interacts with antibody M to form a complex ML, the concentrations at equilibrium are governed by Kd = [M]*[L]/[ML] where Kd, the dis-
sociation constant, characterises the affinity of the antibody. Defining Mo = [M] + [ML] as the maximum binding, the relationship [ML] = M0*[L]/(Kd + [L])
determines the hyperbolic standard curve (78). By this relationship, in a radioimmunoassay, the log of the concentration of unlabelled peptide is linearly pro-
portional to logit (B/Bo) where B is the counts measured ([M]), B0 is the maximum number of counts measured in the absence of unlabelled peptide ([M0]),
and logit (y) = loge(y/(1  y)). (B) Illustrating (in blue) the relationship between log peptide concentration and B when B0 and Kd are given values of 100. Sam-
ples are contained not in assay buffer but in a sample matrix that can affect either Bo or Kd. If the matrix reduces the affinity of the antibody, the true con-
centrations of ligand will relate to measured levels by a curve that is displaced to the right of the standard curve: the green curve in (B) simulates the effect
of changing Kd from 100 to 150. In an immunoassay, this leads to an underestimation of levels, as shown by the green line in (C), which plots the true con-
centration against that inferred from the standard curve. If the matrix reduces the antibody available for binding with the ligand, the true concentrations will
relate to measured levels by a curve that is ‘compressed’. The orange curve in (B) simulates the effect of interference that changes Bo from 100 to 22; such an
assay will report an erroneous high basal level (360 pg/ml) and will exaggerate the levels of any ligand present, by 4.5-fold in the example shown by the green
line in (C). Plasma proteins may affect both Kd and Bo. The grey curves in (B) and (C) show the effects of increasing Kd to 150 and reducing B0 to 22. The
erroneous baseline level is unaffected, but the exaggeration is reduced; here, the gain is three-fold.
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half-life of approximately 4.5 min, again mainly by the kidneys and
liver (105). In dogs, rather than measure vasopressin by either
radioimmunoassay or bioassay, Ang and Jenkins (106) injected radi-
olabelled vasopressin and used thin-layer chromatography and
autoradiography to quantify labelled vasopressin in plasma samples:
it disappeared with an initial half-life of 3 min and a later half-life
of 13 min.
In man, after an acute injection of vasopressin, bioactivity disap-
peared with an initial half-life of 5.6 min (43). Later studies using
radioimmunoassay indicated that vasopressin disappeared from the
circulation with a bi-exponential decay (107). The fast phase had a
half-life of 5.4 min and a distribution volume close to the plasma
volume; the slower phase had a half-life of 78 min with a distribu-
tion volume close to the extracellular fluid volume. In patients with
chronic renal failure, the clearance is much slower: MCR is reduced
by approximately half (108), which is consistent with the conclusion
that vasopressin is mainly cleared from the circulation through the
kidneys.
Clearance of oxytocin
Ginsburg and Smith (49), using a rat uterus bioassay, found that,
when oxytocin was added to rat plasma in vitro at 37 °C, it was
relatively stable, losing just 6–13% of biological activity after
40 min of incubation. By contrast, when oxytocin was injected into
rats, the biological activity disappeared with a half-life of 1.65 min.
In nephrectomised rats, bioactivity declined with a half-life of
approximately 3 min in the first 7 min, and much more slowly
thereafter. When the splanchnic vessels were also ligated, the initial
decline was not further changed but, after 7 min, oxytocin concen-
trations ‘stuck’ at a high, steady level. Ginsburg and Smith deduced
that, when oxytocin enters the circulation, it is rapidly removed by
the kidneys and liver. Without these organs, injected oxytocin dif-
fuses within approximately 7 min throughout the extracellular fluid,
where it is degraded only very slowly.
In the baboon, oxytocin clearance was also consistent with a
two-compartmental system, corresponding to the plasma volume
and the extravascular fluid volume. The initial half-life in the first
phase of distribution was approximately 1 min, followed by a ter-
minal elimination half-life of approximately 10 min (109).
In man, Fabian et al. (43) measured oxytocin with a mammary
gland bioassay and studied its clearance after the end of an i.v.
infusion. Bioactivity disappeared with a half-life of 4.8 min with a
distribution volume of 10.5 ml/100 g, which is close to the extracel-
lular fluid volume, whereas an acute large injection disappeared with
a half-life of 3.2 min and a distribution volume of 7.4 ml/100 g.
Ultrafiltration of the plasma indicated that, whereas approximately
30% of similarly infused vasopressin was bound to large molecules,
there was no apparent binding of oxytocin. In vitro, oxytocin bioac-
tivity was stable, as found in rats (49); only approximately 20% was
lost after 24 h at 37 °C.
Thornton et al. (110) measured oxytocin by radioimmunoassay in
extracted plasma from pregnant and post-partum women, taking
careful precautions to inactivate oxytocinase. Within 30 min, infu-
sions of 17.9 ng/min in pregnant women raised oxytocin
concentrations by 3.5 pg/ml from a basal level of 1.5 pg/ml. In post-
partum women, the same increase could be matched by infusion of
just 4.3 ng/min. The corresponding MCRs were 5.7 l/min in pregnant
women but only 1.3 l/min in postpartum women, suggesting that
oxytocinase indeed has a major effect on the clearance of oxytocin.
Thus, bioassays, radioimmunoassays and evidence of the sensitiv-
ity of peripheral targets to oxytocin and vasopressin all converged
on the conclusion that, in mammals, both hormones are normally
present in the circulation at < 10 pg/ml. The pharmokinetics are
consistent with a two-compartment model, where these hormones
are secreted into the blood are cleared by the kidneys and liver,
and diffuse between the blood and extravascular fluid. Bolus injec-
tions disappear rapidly, with an initial half-life that varies between
species and with physiological state: in the rat, both hormones dis-
appear with an initial half-life of approximately 2 min; in man,
oxytocin has a half-life of 4–10 min, except in pregnancy, when
oxytocinase shortens this to 2–3 min. As a proportion of body
weight, the rat pituitary contains much more oxytocin and vaso-
pressin than the human pituitary and, in rats, as in other small
mammals, circulating levels are higher. In man and other large ani-
mals, lower circulating concentrations are compensated for by
higher sensitivity of the peripheral targets.
ELISAs
Competitive ELISAs work on the same principles as radioimmuno-
assays, with the advantages that they do not use radioactive mate-
rials, require less investment in equipment, and the biotinyl–
oxytocin is more stable than radiolabelled oxytocin. However, ELISAs
are similarly susceptible to plasma interference. Discussing the
problems that arise in measurements in human plasma, Bjerner
et al. (111) characterised the first step of any immunoassay as ‘the
encounter between a limited number of immobilised animal anti-
bodies in close relation to each other and a huge concentration of
human immunoglobulins and non-immunoglobulins containing a
broad spectrum of reactivities’. The binding of plasma proteins to
an immunoglobulin can hinder its ability to bind an antigen, reduc-
ing its affinity, and/or may completely prevent some of the anti-
body from binding to antigen. With a reduction in maximum
binding, an assay will report erroneously high values even in the
absence of any antigen, and will exaggerate measurements of
added antigen. The effect of a reduction in affinity is different; in
this case, the assay will under-report added antigen. In both cases,
there will be a linear relationship between the amount of oxytocin
added and the amount measured, although the slope will depend
on the nature of the interference (Fig. 1).
In 1994, the first ELISA suitable for measuring oxytocin in plasma
was developed by Prakash et al. (112). They recognised that plasma
components interfered by reducing antibody binding, and so they
constructed standard curves in hormone-stripped plasma. Their
assay could detect plasma concentrations above 1.25 pg/ml, and
they used it to measure oxytocin in the cow during milking, com-
paring the results with measurements of the same samples by
radioimmunoassay after plasma extraction. The two methods
showed very close agreement.
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The ELISAs in most widespread use are marketed by Enzo, who
draw attention to problems of plasma matrix interference, illustrate
the benefits of plasma extraction, and ‘strongly recommend’ that
users extract plasma samples. They state that it might be possible
to dilute plasma samples enough to minimise interference (suggest-
ing at least an eight-fold dilution) but warn that the user ‘must
verify’ that these dilutions are appropriate for their samples (113).
This advice has been largely ignored. Many studies have used this
assay on unextracted human plasma, reporting mean concentra-
tions of oxytocin and vasopressin of typically 100–500 pg/ml
(3–6,114). Those that have diluted samples have done so by less
than the manufacturer’s recommendations, without confirming that
their dilution is adequate.
These values are inconsistent, by two orders of magnitude, with
both bioassays of oxytocin and vasopressin and with radioim-
munoassay measurements on extracted samples. They are also
inconsistent with the known sensitivity of peripheral targets to oxy-
tocin and vasopressin, and with what is known of the production,
storage and clearance of these hormones. A plasma concentration
of 350 pg/ml oxytocin in man implies a total blood content of
approximately 1 lg (given a plasma volume of 3 l) and, for a half-
life of 10 min, this implies a secretion (and production) rate of
500 ng/min, or 720 IU/day. Jones and Pickering (115) measured the
rate of hormone production in the rat by giving rats an intracister-
nal injection of tritiated tyrosine to label newly synthesised oxy-
tocin and vasopressin. Radioactive hormone began to appear in the
posterior pituitary within 2 h, and, after 7 days, the specific
radioactivity of each hormone declined with a half-life of approxi-
mately 13 days. They thus calculated that oxytocin must be
secreted at 18.7 mU/day and vasopressin at 28.9 mU/day. Assuming
a half-life of 2 min, this is consistent with plasma concentrations
of 5–10 pg/ml for each hormone. Thus, to sustain a plasma con-
centration of 350 pg/ml in man, oxytocin must be produced at
40 000 times the rate measured in the rat. Given a difference in
pituitary mass and oxytocin content of just 40-fold, this seems
beyond plausibility.
Three studies have compared measurements of oxytocin in the
same samples by the same ELISA, with and without extraction
(101,116,117). Robinson et al. (116) measured oxytocin levels in
seals: in extracted samples, they found plasma levels of approxi-
mately 8 pg/ml, compared to 300 pg/ml in unextracted samples
collected in heparin vacutainers or 540 pg/ml in unextracted sam-
ples collected in ethylenediaminetetraacetic acid (vacutainers). There
was no correlation between the measurements in extracted and
unextracted samples. Christensen et al. (117) measured plasma
samples using both a radioimmunoassay and the Enzo ELISA.
Radioimmunoassay of extracted samples returned mean levels of
1.1 pg/ml, and levels measured in the same samples spiked with
oxytocin were consistently higher by the expected amount. Without
sample extraction, the ELISA measured basal levels of 97 pg/ml,
failed to recover spiked levels accurately, and the measurements
did not correlate with levels measured in extracted samples. Szeto
et al. (101) also found no correlation between levels in extracted
and unextracted samples. Spiking unextracted samples with oxy-
tocin resulted in a 3.5-fold exaggeration of the measurements,
indicating that plasma factors interfere with the binding of anti-
body to oxytocin (Fig. 1).
Claims that the Enzo ELISA is a valid way of measuring oxytocin
in unextracted plasma do not rest on manufacturer’s advice,
which, as we have noted, strongly recommends extraction, but,
instead, converge on two papers, neither of which actually investi-
gated human plasma at all. Kramer et al. (118) measured oxytocin
in plasma of rats and prairie voles, reporting basal levels of
79 pg/ml in rats and 264 pg/ml in voles, which are both much
higher than measured by radioimmunoassay in extracted samples.
They showed that pooled samples from prairie voles diluted in par-
allel with the assay standard curve. However, nonspecific binding
to antibody is also governed by the law of mass action and,
accordingly, erroneous levels can dilute in parallel to the standard
curve except at extreme dilutions: what constitutes a sufficient
dilution will depend on the affinity of the particular interfering
factor for the antibody. Kramer et al. (118) also found that, in
voles injected s.c. with 5 lg of oxytocin, plasma levels reached
20 ng/ml. Oxytocin injected s.c. is expected to distribute through-
out the extracellular fluid volume, which, for a vole weighing
approximately 70 g is < 10 ml. An injection of 5 lg should there-
fore increase plasma concentrations by > 500 ng/ml, much more
than reported, suggesting that vole plasma proteins also reduce
the affinity of the antibody.
Carter et al. (119) further reported that, in voles, the ELISA
measured spiked levels of oxytocin with a gain of 0.79. This is
consistent with a reduction in antibody affinity, although not suf-
ficient to account for the discrepancy between expected and mea-
sured oxytocin in Kramer’s measurements. In fractions separated
by high-performance liquid chromatography (HPLC), apparent
immunoreactivity appeared only in fractions that eluted with oxy-
tocin, suggesting that there was no plasma interference. However,
the same method had previously been used by Wismer Fries et al.
(120) in a study that reported levels of oxytocin in human urine
approximately one million times higher than found in previous or
subsequent reports. According to Anderson (121), that discrepancy
arose from the limited analytical selectivity of rapid chromato-
graphic separation and the low sensitivity of ultraviolet absor-
bance detection.
Carter et al. (119) also claimed that four previous studies had
validated the ELISA in unextracted plasma. Of those four studies,
three neither report, nor cite any validation of the assay; the fourth
(122) found higher plasma concentrations of oxytocin in rats than
previously reported, and so conducted ‘a control study with known
concentrations of oxytocin’. No details are provided except that the
ELISA kit ‘had a detection sensitivity of 3.21 pg/ml’. Because they
had found basal levels of 400 pg/ml in unextracted plasma, it
appears that their control must simply have been a verification of
assay performance in assay buffer.
Finally, Carter et al. (119) claimed a biological validation for the
ELISA in reporting that breastfeeding in women lowered salivary
concentrations of oxytocin. Because suckling-induced oxytocin
release is indispensable for milk let-down in mammals (123), it is
difficult to understand how such an anomalous observation quali-
fies as a validation.
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Other methods of measurement
Attempts have been made to develop assays using liquid chro-
matography-tandem mass spectrometry (LC-MS/MS). Such methods
also have problems with sample matrix interference (124). As Zhang
et al. (125) recognised, ‘One common challenge in biomarker analy-
sis is to select an appropriate surrogate matrix to prepare the stan-
dard curve, which is free of target analytes and is identical or
similar to unknown sample matrix with regard to ionisation effects
and extraction recovery’. Plasma oxytocin was measured using
human plasma diluted with water (1 : 6) as a surrogate matrix, and
basal levels of 2.4 pg/ml for human but 298 pg/ml for rat were
reported; these high levels in the rat may indicate that human
plasma is not a suitable surrogate matrix for measurements in rat.
A similar LC-MS/MS assay was used to measure vasopressin in
human plasma, again using human plasma diluted with water
(1 : 6) as a surrogate matrix, and this reported levels < 2 pg/ml in
children (126). Tsukazaki et al. (127) developed an LC-MS/MS assay
for vasopressin, and showed that, correcting for plasma matrix
effects, this assay gave close quantitative agreement with radioim-
munoassay results from extracted human plasma samples, and had
higher sensitivity and needed smaller sample volumes. So far, how-
ever, LC-MS/MS assays have not been developed to become a prac-
ticable alternative for general use.
Recently, many studies have measured copeptin in plasma as a
surrogate marker for vasopressin (128). Copeptin is a large glyco-
protein product of the vasopressin precursor, and its large size
(37 kDa) makes it much easier to measure. As a fragment of the
vasopressin precursor, it is released in equimolar amounts as vaso-
pressin: it has a similar half-life to vasopressin in normal individu-
als and, in plasma, it circulates at approximately equimolar
concentrations as the vasopressin that is measured by radioim-
munoassay in extracted samples (129). No comparable surrogate
marker for oxytocin has yet been identified.
Recommendations for validation of assays
Plasma matrix proteins interact differently with different antibod-
ies: there is no single ‘radioimmunoassay’ and no single ‘ELISA’,
and their susceptibility to plasma interference will vary with the
antibody. Plasma proteins differ from individual to individual and
differ substantially from species to species, and so any assay in
unextracted plasma should be validated for the species in which
it is measured and, ideally, in the individual in which it is
measured.
It is natural to expect that measured levels should be consistent
with measures of bioactivity. For vasopressin in man, testing this is
straightforward. After a gastric water load, antidiuretic activity is
minimal, as is evident from the production of highly dilute urine;
conversely, high antidiuretic activity is evident after a modest per-
iod of dehydration from the production of highly concentrated
urine. Thus, samples in these two conditions should show the
extremes of very low and near maximal physiological levels. From
bioassays and well-validated radioimmunoassays, this range is from
1 to approximately 10 pg/ml in man. In mice or rats, validation
could be supported by measurements in gene knockout animals or
hypophysectomised animals, where vasopressin and/or oxytocin are
completely absent.
There are no known conditions in which oxytocin is absent or
grossly elevated in man. However, given the sensitivity of peripheral
targets in man to very low concentrations, levels exceeding 10 pg/ml
should be treated with scepticism. Levels from an individual could be
verified by constructing a standard curve in hormone-stripped plasma
from that individual (93), although it would be impractical to do this
for every individual sampled.
Whatever assay is employed, consideration must be given as to
how the sample matrix affects it. Analytical verification by HPLC
with chromatographic separation (78) can confirm that measure-
ments reflect the actual peptide, although care is needed to ensure
that all high molecular weight proteins are eluted from the column
and are checked for assay interference. There should be quantitative
agreement between the amount of hormone in the appropriate
fraction, and the level reported by the assay.
Samples with high levels will not dilute in parallel to the stan-
dard curve if the levels arise from factors such as high salt levels
or pH that interfere nonlinearly with antibody binding, although
this test may not recognise protein interference that blocks anti-
body recognition of the antigen. Such interference will be apparent
if, when samples are spiked with known amounts of hormone, the
assay recovers amounts different to the expected amount. However,
the absence of a difference is not conclusive because interference
that reduces antibody affinity will lead to underestimation of added
hormone, whereas interference that blocks antibody recognition will
lead to overestimation, and both effects are likely to be present.
Measuring oxytocin or vasopressin in cerebrospinal fluid, urine or
saliva should have fewer problems because of the relative absence
of proteins but, in urine, high salt concentrations may cause prob-
lems. In a steady-state, unbound oxytocin and vasopressin should
distribute in extravascular fluids, and measurements in saliva might
be useful for estimating steady-state secretion (119,130,131). How-
ever, matrix interference can be a problem in measurements in sal-
iva at least for some antibodies, again because of nonspecific
interference with antibody–antigen binding (132).
Conclusions
The high levels of oxytocin and vasopressin reported by immunoas-
says in unextracted plasma probably arise from plasma protein
interference with antibody binding that produces a high and wholly
erroneous baseline. If so, these assays are, for unextracted plasma,
no more than a random number generator, returning arbitrary val-
ues with a high variance and a skewed distribution. Nevertheless,
this extensive literature is not without interest. If our analysis is
correct, then this literature becomes a test of the conclusion of
Ioannidis (133) that most published results are false, arising from a
combination of underpowered studies, confirmation bias and publi-
cation bias, where apparent statistical significance is generated by
‘undisclosed researcher degrees of freedom’ (134). Indeed, none of
the four studies cited in the Introduction (3–6) as examples of the
use of ELISAs to measure oxytocin and vasopressin in unextracted
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samples made any correction for multiple comparisons in their
analyses.
The current impetus for measuring vasopressin and oxytocin in
plasma derives from the assumption that such measurements are
informative of the release of these peptides in the brain. The falla-
cies in this supposition have been discussed elsewhere (2). A recent
systematic review has concluded that studies using ELISA on unex-
tracted samples have produced no convincing evidence that periph-
eral vasopressin or oxytocin might be reliable biomarkers in
psychiatric disorders (135). It would be a pity if studies based on
unsound presumptions and erroneous measurements are taken as
evidence that disturbances in peptide release within the brain are
not involved in these conditions.
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